Proniras

Executive Summary

Proniras Corporation is a clinical-stage biotechnology company developing small-molecule therapeutics for substance use and central nervous system (CNS) disorders. Founded in 2015 and headquartered in Seattle, the company's lead program, tezampanel, is a glutamate antagonist designed to treat opioid withdrawal and addiction without directly targeting the opioid system, offering a novel mechanism with potential for reduced abuse liability. The company recently completed a Series B financing, which is expected to support ongoing clinical development. Tezampanel has completed Phase 1 trials, and Proniras is poised to advance the program into Phase 2 studies. The company's focus on addressing the opioid crisis aligns with significant unmet medical need and regulatory support, positioning it as a potential player in the addiction therapeutics space. However, as a private, early-stage biotech, Proniras faces typical risks related to clinical trial outcomes, regulatory hurdles, and funding requirements.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 clinical data readout for tezampanel in opioid withdrawal65% success
• Q2 2027Announcement of partnership or licensing deal for tezampanel30% success
• Q1 2027Initiation of Phase 2 trial for tezampanel50% success